ArticleAbdominal radiology (New York)2026
Identifying a better-prognosis pancreatic cancer from its benign inflammatory mimic: a machine learning approach with contrast-enhanced ultrasound for early intervention.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeHypervascular pancreatic ductal adenocarcinoma (PDAC) and mass-forming pancreatitis (MFP) represent a classic diagnostic mimicry on contrast-enhanced ultrasound, as both exhibit similar arterial-phase hyperenhancement, precluding reliable visual distinction. Crucially, the hypervascular PDAC subtype is associated with a more favorable prognosis, rendering its accurate identification from its benign inflammatory mimic (MFP) a clinically significant priority for early and appropriate intervention. This study aimed to develop and validate a small-sample-oriented machine learning framework leveraging quantitative time-intensity curve (TIC) features to achieve this precise differentiation. MATERIALS AND
methodsWe retrospectively included 152 patients with pathologically confirmed lesions who underwent CEUS between September 2017 and April 2024 (85 hypervascular PDAC, 67 MFP). A temporally separated split was used: 122 patients (2017-2022) formed the training cohort and 30 patients (2023-2024) served as the internal test cohort. Paired TICs were generated from the lesion and adjacent normal pancreatic parenchyma, and 22 quantitative difference/ratio features describing enhancement amplitude, temporal kinetics and curve morphology were extracted. Based on independent-samples t-tests and clinical interpretability, five representative TIC features were selected to train six classical classifiers (logistic regression, support vector machine, k-nearest neighbors, random forest, naïve Bayes, and decision tree). Model performance was assessed by stratified 10-fold cross-validation on the training cohort and by testing on the temporally separated cohort.
resultsIn nested cross-validation, all models achieved AUCs of approximately 0.89-0.92. On the test cohort, AUCs ranged from about 0.83 to 0.92, with logistic regression performing best (AUC 0.915). Overall, the six classifiers showed broadly comparable discrimination.
conclusionA machine-learning model built on a small set of physiologically interpretable CEUS-TIC features can provide stable and explainable quantitative support for differentiating hypervascular PDAC from MFP, even under limited-sample conditions.
Indexed as
Identifiers
41714354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.